CY-09

产品说明书

Print
Chemical Structure| 1073612-91-5 同义名 : -
CAS号 : 1073612-91-5
货号 : A234660
分子式 : C19H12F3NO3S2
纯度 : 99%+
分子量 : 423.429
MDL号 : MFCD31619349
存储条件:

Pure form Sealed in dry,2-8°C

In solvent -20°C:3-6个月-80°C:12个月

溶解度 :

DMSO: 145 mg/mL(342.44 mM),注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

动物实验配方:
生物活性
描述 NOD-like receptor (NLR) family are a group of inflammasomes formed by innate immune sensors. NLRP3 is a member of NLR family and its aberrant activation is involved in the pathogenesis of a variety of human diseases. CY-09 is a NLRP3 inhibitor that blocks the ATPase activity of the NLRP3 NACHT domain, which is essential for the oligomerization of NLRP3, resulting in the suppression of NLRP3 inflammasome activation. CY-09 shows inhibitory activities against five major cytochrome P450 enzymes 1A2, 2C9, 2C19, 2D6, and 3A4 with IC50 values of 18.9, 8.18, >50, >50, and 26.0 µM, respectively. CY-09 at 1-10 µM dose-dependently inhibited the monosodium urate (MSU), nigericin, ATP-induced caspase-1 activation and IL-1β secretion in LPS-primed BMDMs. Cytosolic LPS-induced noncanonical NLRP3 activation in BMDMs was also inhibited by CY-09 treatment (1-10µM). CY-09 at the doses of 1-10µM effectively suppressed nigericin-induced ASC oligomerization in BMDMs, but showed no effect on nigericin-induced mitochondrial damage and reactive oxygen species production. Treatment with 5-10µM CY-09 in HEK-293T cells inhibited the interaction of Flag–NLRP3 and mCherry–NLRP3, suggesting the inhibitory function of CY-09 on NLRP3 oligomerization. CY-09 inhibited the ATPase activity of purified NLRP3 at doses of 0.1-1µM, and the Kd value between CY-09 and purified GFP-NLRP3 was about 500nM. In a mouse model of cryopyrin-associated autoinflammatory syndrome, treatment of CY-09 (40mg/kg) efficiently suppressed MSU injection-induced IL-1β production and neutrophil influx[1].
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

2.36mL

0.47mL

0.24mL

11.81mL

2.36mL

1.18mL

23.62mL

4.72mL

2.36mL

参考文献

[1]Jiang H, He H, Chen Y, Huang W, Cheng J, Ye J, Wang A, Tao J, Wang C, Liu Q, Jin T, Jiang W, Deng X, Zhou R. Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders. J Exp Med. 2017 Nov 6;214(11):3219-3238. doi: 10.1084/jem.20171419. Epub 2017 Oct 11. PMID: 29021150; PMCID: PMC5679172.